Quarterly ResultMay 13, 2026, 04:22 PM
Aptevo Therapeutics Raises Going Concern Doubt; Q1 Net Loss $(6.7)M
AI Summary
Aptevo Therapeutics Inc. reported a net loss of $(6.7) million for the first quarter of 2026, an increase from $(6.4) million in the prior year. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows from operations. Cash and cash equivalents decreased to $14.5 million as of March 31, 2026, despite raising $0.9 million through common stock issuance in the quarter and an additional $0.2 million subsequently.
Key Highlights
- Aptevo Therapeutics disclosed substantial doubt about its ability to continue as a going concern.
- Q1 2026 net loss was $(6.7) million, compared to $(6.4) million in Q1 2025.
- Cash and cash equivalents stood at $14.5 million as of March 31, 2026.
- Net cash used in operating activities was $(8.0) million for the three months ended March 31, 2026.
- The company raised $0.9 million in net proceeds from common stock issuance in Q1 2026.
- Research and development expenses increased to $(3.9) million in Q1 2026.
- General and administrative expenses were $(2.9) million in Q1 2026.
- Accumulated deficit reached $(281.9) million as of March 31, 2026.